Azithromycin is Preferred Over Rifaximin for Acute Gastroenteritis
For acute gastroenteritis in adults, azithromycin should be used rather than rifaximin, particularly when the severity warrants antibiotic therapy or when invasive pathogens cannot be excluded.
Treatment Algorithm Based on Severity
Mild Gastroenteritis
- No antibiotics recommended 1
- Use loperamide or bismuth subsalicylate for symptom management
- Reserve antibiotics only if symptoms progress
Moderate to Severe Gastroenteritis
Azithromycin is the first-line choice (Strong recommendation, high level of evidence) 1:
- Dosing: Single 1-gram dose OR 500 mg daily for 3 days 1
- Covers both watery and invasive diarrhea
- Effective against fluoroquinolone-resistant Campylobacter, Shigella, Salmonella, and diarrheagenic E. coli
Rifaximin has significant limitations:
- Only for non-invasive, non-dysenteric diarrhea (Weak recommendation, moderate level of evidence) 1
- Fails in up to 50% of cases with invasive pathogens 1
- Not appropriate if fever, bloody stools, or mucus present 2
- Since 10-20% of acute gastroenteritis involves invasive pathogens (Campylobacter, Salmonella, Shigella), rifaximin cannot be reliably used empirically 1
Key Clinical Decision Points
When Azithromycin is Mandatory
- Any dysentery (bloody/mucoid stools) - Strong recommendation 1
- Fever greater than mild - suggests invasive pathogen 1
- Severe incapacitating diarrhea 1
- Unknown travel history or high-risk regions (Southeast Asia, India, sub-Saharan Africa) where fluoroquinolone-resistant organisms predominate 1
When Rifaximin Could Be Considered (Rarely)
- Confirmed non-invasive watery diarrhea in low-risk settings
- No fever, no blood, no mucus 2
- Known E. coli predominance (specific epidemiologic context only)
- Even then, azithromycin remains equally effective and safer empirically 1
Critical Pitfalls to Avoid
Do not use rifaximin if:
- You cannot definitively exclude invasive pathogens clinically
- Patient has fever or systemic symptoms
- Any blood or mucus in stool
- Travel to high-risk areas for Campylobacter/Shigella 1
The FDA label explicitly states rifaximin is only for noninvasive E. coli and should not be used with fever or bloody diarrhea 2. Since clinical differentiation between invasive and non-invasive causes is unreliable without testing, and testing delays treatment, azithromycin provides broader, safer empiric coverage 1.
Resistance and Safety Considerations
Azithromycin has demonstrated superiority over fluoroquinolones in regions with high fluoroquinolone resistance (>90% in some areas), with comparable cure rates for shigellosis and better outcomes for Campylobacter 1. It is well-tolerated with minimal side effects (3% nausea/vomiting) 1. Rifaximin, while having an excellent safety profile due to minimal absorption, simply cannot address the invasive pathogens that account for a substantial minority of cases 1.
Single-dose azithromycin regimens are supported by strong evidence for both moderate and severe diarrhea, improving adherence 1.